Hyperion Lowers Price, Adds Shares in $50M IPO
Orphan disease firm Hyperion Therapeutics Inc. priced its initial public offering (IPO), shaving the price from the midpoint of $12 per share cited in its amended S-1 filing earlier this month to $10 per share – $1 below the proposed range – but upsizing the offering from 4.2 million to 5 million shares.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter